Singh, who opened up the economy as finance minister and served as prime minister for two consecutive terms, died on Thursday at the age of 92. "History will forever honour his pivotal role in the transformative 1991 reforms that reshaped India and opened its doors to the world.
'I have added to the covid count by testing positive. Mild symptoms and I hope it stays that way,' the 67-year-old biotechnology industry veteran said in a tweet.
Industry leaders, including Mahindra Group chairman Anand Mahindra, RPG Enterprises chairman Harsh Goenka and Biocon Ltd chairperson Kiran Mazumdar-Shaw on Monday came out in support of the Agnipath scheme, saying it has large potential for employment of youth in the corporate sector. Mahindra also expressed dismay over the violence against the scheme while asserting that the farm equipment to aerospace conglomerate welcomes the opportunity to recruit trained, capable and young people under the programme. The Agnipath scheme, announced on June 14, provides for the recruitment of youths between the age bracket of 17-and-half years to 21 for only four years with a provision to retain 25 per cent of them for 15 more years.
India's biotechnology major Biocon Ltd, is all set to make its way to Pakistan's pharmaceutical market by 2008 with its oncology drug BIOMAb EGFR.
Leading biotech firm, Biocon Ltd, on Tuesday said it would invest $10 million (about Rs 45 crore) in the next 12 months to expand its facilities.
Learn how the founder of India's first and largest biotechnology company dealt with failure and achieved success.
The Bengaluru-based firm has entered into a definitive agreement with Mylan for an exclusive strategic collaboration for the global development and commercialisation of generic versions of its three insulin analog products, Biocon Ltd said in a statement.
The company's share price touched a 52-weeks high on Monday on speculation that the global drug major, Pfizer, may buy stake or strike a marketing deal with the company.
Clinical trials, agri-biotech and bio-fuels are becoming opportunities. There are a lot of growth drivers and trigger points which, she said, will deliver in the next five years.
Researchers and scientists in India would have to be innovative if the country wished to unleash its vast intellectual potential, chairman and managing director of Biocon Ltd Kiran Mazumdar Shaw said on Saturday.
Biocon Ltd on Wednesday said it has signed a product licensing agreement with Bentley Pharmaceuticals, Inc, a technology-based specialty pharmaceutical and drug delivery company for Bentley's intranasal spray formulation for administering insulin.
Biotech major Biocon Ltd's net profit for the quarter ended June 2004 zoomed by 112 per cent at Rs 48.6 crore as compared to Rs 22.9 crore in the first quarter of the previous fiscal.
Blaming it on the "ineffective" bureaucracy and "very confused" ruling coalition in Karnataka, Kiran Mazumdar-Shaw, managing director of Biocon Ltd on Friday said infrastructural woes were impeding the growth of Bangalore.
Leading bio-technology company Biocon Ltd on Monday said its research development partner, Nobex Corporation, has filed for bankruptcy in the US.
Biocon Ltd ill seek Drug Controller General of India's approval for its novel monoclonal antibody indicated towards the treatment of head and neck cancer, Biomab EGFR.
Bangalore-based Biocon Ltd and a US biotech firm Nobex Corporation will jointly develop an oral insulin product for the treatment of diabetes.
Biocon Ltd on Tuesday said it has earned the distinction of being the only Asian biopharma company to feature among the top biotechnology employers in the world as ranked by Science magazine.
On course to become India's first biotech company to be listed on a stock exchange, Bangalore-based Biocon Ltd on Thursday kicked off a roadshow for its initial public offering that opens on March 11.
Leading biotechnology firm Biocon Ltd on Tuesday reported a 22 per cent decline in profit after tax for the half year ended September.
"We are growing fast. We are planning to double the manpower to 4,000 from 2,000 at present. Within a very short period we increased the number of employees by 500 to reach 2000," Biocon Chairman and Managing Director Kiran Mazumdar Shaw said.
The initial public offering of the shares of Bangalore-based Biocon Ltd has received bids five times the one crore shares available for subscription within an hour of opening of the biding process on Thursday.
'If the government doesn't subsidise, it would be a huge setback in the fight against COVID-19'
Testing only those with symptoms is not such a great idea. A lot of asymptomatic people are also positive. Its also important to do some amount of random testing in the clusters. You need to do lot more testing. The more you test, the more positives you get. Only redeeming feature is that the number of those getting into ICU or dying is not huge, she said.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Roche said the Indian regulatory authorities had approved Biocon and Mylan's products as Trastuzumab, but it was unclear if these met the criteria for biosimilar products.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances